Martin v. Med-Dev Corporation and Finley

CourtCourt of Chancery of Delaware
DecidedOctober 27, 2015
DocketCA 10525-VCP
StatusPublished

This text of Martin v. Med-Dev Corporation and Finley (Martin v. Med-Dev Corporation and Finley) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Martin v. Med-Dev Corporation and Finley, (Del. Ct. App. 2015).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

MICHAEL G. MARTIN, : : Plaintiff, : : v. : C.A. No. 10525-VCP : MED-DEV CORPORATION and : THOMAS J. FINLEY, : : Defendants. :

MEMORANDUM OPINION

Date Submitted: July 28, 2015 Date Decided: October 27, 2015

James S. Yoder, Esq., WHITE AND WILLIAMS, LLP, Wilmington, Delaware; Kevin F. Berry, Esq., Kimberly A. Havener, Esq., WHITE AND WILLIAMS, LLP, Philadelphia, Pennsylvania; Attorneys for Plaintiff Michael G. Martin.

Michael P. Kelly, Esq., Andrew S. Dupre, Esq., Benjamin A. Smyth, Esq., McCARTER & ENGLISH, LLP, Wilmington, Delaware; Attorneys for Defendants Med-Dev Corporation and Thomas J. Finley.

PARSONS, Vice Chancellor. This case involves a dispute over the management of a medical device company.

Members of the company‟s board of directors accused the Chairman and CEO—the

plaintiff in this action—of misappropriating company funds, leading to his eventual

resignation. Although the plaintiff believed his resignation was contingent on the

appointment of two investors to the company‟s board of directors, the other directors—

one of whom, along with the company, is a defendant in this action—took the resignation

as unconditional.

The plaintiff brought this action under Section 225 of the Delaware General

Corporation Law (“DGCL”)1 to contest the validity of his resignation from the

company‟s board of directors and to invalidate the appointment of the director who

replaced him as the Chairman. Both parties also seek an award of attorneys‟ fees and

expenses against the other under the bad faith exception to the American Rule.

The trial was conducted on June 10 and 11, 2015. After post-trial briefing, I heard

oral argument on July 28. For the reasons that follow, I conclude that the plaintiff should

be reinstated as the company‟s Chairman, but that the director who replaced him as the

Chairman should remain on the board. The defendants are entitled to partial attorneys‟

fees and expenses against the plaintiff based on a frivolous claim the plaintiff brought

against them and pursued until he abandoned it just before trial. I deny the plaintiff‟s

request for attorneys‟ fees and expenses from the defendants.

1 8 Del. C. § 225.

1 I. BACKGROUND2

A. Parties

Plaintiff, Michael G. Martin, is the sole incorporator of Med-Dev Corporation

(“Med-Dev” or the “Company”). Martin3 initially served as the Chief Executive Officer

(“CEO”) and Chairman of Med-Dev‟s board of directors (the “Board”). He purportedly

resigned from those posts on April 19, 2014. The effect of that resignation and Martin‟s

claim for reinstatement as the Chairman of the Board are at issue in this action.

The defendants are Med-Dev and Thomas J. Finley (collectively, “Defendants”).

Med-Dev, a Delaware corporation based in Scranton, Pennsylvania, is a medical device

company that was founded in 2012. Finley4 has at all times since the Company‟s

inception served as a member of the Board and Med-Dev‟s President. Finley replaced

Martin as the CEO upon his purported resignation.

Relevant non-parties to this action include William Peters, M.D., and Michael

Moore, M.D., Ph.D., who were the other two initial members of the Board, and George

Albanese, a Company stockholder who was appointed to the Board on January 16, 2014

2 Citations to testimony presented at trial are in the form “Tr. # (X),” with “X” representing the surname of the speaker, if not clear from the text. Exhibits will be cited as “JX #,” and facts drawn from the parties‟ pretrial Joint Stipulation are cited as “JS ¶ #.” 3 All references to “Martin” throughout this Memorandum Opinion should be understood to mean Michael G. Martin. Any reference to Mick Martin, another of the Company‟s original stockholders, will include his first and last name. 4 All references to “Finley” throughout this Memorandum Opinion should be understood to mean Thomas J. Finley. Any reference to Finley‟s brother, Kevin Finley, will include his first and last name.

2 and later replaced Martin as the Chairman after his purported resignation. Like Martin,

Albanese‟s current status as a director and the Chairman of the Board is at issue in this

action. In conjunction with his resignation from the Board, Martin attempted to cause the

addition to the Board of Gregory Rainey and Edward Lipes—stockholders of Med-Dev

with experience working in the medical device industry. Joseph Tomasek was the

Company‟s corporate counsel from 2012 until December 2014.

B. Facts

1. Background of the Company

Med-Dev was formed in June 2012 to distribute a novel intra-nasal medical device

(the “Clip”) that was intended to serve as a non-antibiotic treatment for nasal methicillin-

resistant Staphylococcus aureus infections. The Clip was developed by Moore and was

to be handmade using a silver impregnated fabric material for placement on the nasal

septum. In addition to Moore (1,252,500 shares), the Company‟s founders and original

stockholders included Martin (1,252,500 shares), Finley (1,252,500 shares), Peters

(1,252,500 shares), Albanese (1,252,500 shares), Frank LaForgia (710,000 shares), and

Mick Martin (525,000 shares). Finley was the Company‟s original President, and Martin

was its original Chairman and CEO.

Although the Clip was the only product Med-Dev had when it was founded, in

mid-2013, the Company identified an opportunity to obtain the exclusive rights to market

two other, market-ready “Infection Control” medical supply products. The Company

hoped these two new products could be sold through the same distribution channel that

initially was to be used to sell the Clip. Martin believed that to market effectively the two

3 Infection Control products, Med-Dev needed to hire a Chief Operating Officer (“COO”)

with relevant experience. He, therefore, reached out to Eric Suchecki, a recent Company

investor, in or around November 2013, to discuss the possibility of Suchecki serving as

Med-Dev‟s COO. According to Martin, Finley reacted negatively to this suggestion and

stated that he would “not report[] to anybody.”5

2. Albanese’s election to the Board

On January 16, 2014, the Board held a meeting at which Martin presided as

Chairman. At that meeting, a motion was made to expand the Board from four to five

directors and to appoint Albanese as the fifth director. Martin objected, contending that

the nomination and proposed election of Albanese were defective under the Company‟s

bylaws (the “Bylaws”). Martin based his objection on his understanding that the Bylaws

required notice to stockholders before the appointment of a new Board member.

Ultimately, Martin agreed to vote in favor of expanding the Board and Albanese‟s

appointment to the Board, but said that he was “going to get a legal opinion on [the

appointment process‟s compliance with the Bylaws] after the meeting.”6 Hence, the

Board voted unanimously on January 16, 2014 to expand to five members and appoint

Albanese to fill the new seat.

After the January 16 Board meeting, Martin contacted Tomasek and requested a

copy of the Bylaws, which Tomasek forwarded to both Martin and Finley. Martin also

5 Tr. 248. 6 Tr. 156 (Martin).

4 emailed Albanese regarding his initial opposition to Albanese‟s appointment to the

Board, stating, “Somehow, I am being cast as your enemy. Not so, but if you believe it,

so be it.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nevins v. Bryan
885 A.2d 233 (Court of Chancery of Delaware, 2005)
Montgomery Cellular Holding Co. v. Dobler
880 A.2d 206 (Supreme Court of Delaware, 2005)
Alabi v. DHL Airways, Inc.
583 A.2d 1358 (Superior Court of Delaware, 1990)
Hoey v. Hawkins
332 A.2d 403 (Supreme Court of Delaware, 1975)
SmithKline Beecham Pharmaceuticals Co. v. Merck & Co., Inc.
766 A.2d 442 (Supreme Court of Delaware, 2000)
Emerald Partners v. Berlin
726 A.2d 1215 (Supreme Court of Delaware, 1999)
Johnston v. Arbitrium (Cayman Islands) Handels AG
720 A.2d 542 (Supreme Court of Delaware, 1998)
Whittington v. Dragon Group, L.L.C.
991 A.2d 1 (Supreme Court of Delaware, 2009)
Schroder v. Scotten, Dillon Company
299 A.2d 431 (Court of Chancery of Delaware, 1972)
iac/interactivecorp v. O'Brien
26 A.3d 174 (Supreme Court of Delaware, 2011)
Gaffin v. Teledyne, Inc.
611 A.2d 467 (Supreme Court of Delaware, 1992)
American International Group, Inc. v. Greenberg
965 A.2d 763 (Court of Chancery of Delaware, 2009)
Beck v. Atlantic Coast PLC
868 A.2d 840 (Court of Chancery of Delaware, 2005)
Nakahara v. NS 1991 American Trust
718 A.2d 518 (Court of Chancery of Delaware, 1998)
Reid v. Spazio
970 A.2d 176 (Supreme Court of Delaware, 2009)
Paige Capital Management, LLC v. Lerner Master Fund, LLC
22 A.3d 710 (Court of Chancery of Delaware, 2011)
Auriga Capital Corp. v. Gatz Properties, LLC
40 A.3d 839 (Court of Chancery of Delaware, 2012)
Hockessin Community Center, Inc. v. Swift
59 A.3d 437 (Court of Chancery of Delaware, 2012)
Biolase, Inc. v. Oracle Partners, L.P.
97 A.3d 1029 (Supreme Court of Delaware, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Martin v. Med-Dev Corporation and Finley, Counsel Stack Legal Research, https://law.counselstack.com/opinion/martin-v-med-dev-corporation-and-finley-delch-2015.